Introduction
============

Nisin is an antimicrobial peptide which belongs to the lantibiotic class of bacteriocins (Class I) and has been employed as a food preservative in over 50 countries ([@b8]). Lantibiotics are characterized by the presence of unusual amino acid residues, including the lanthionines which give these peptides their name ([@b17]; [@b6]; [@b8]; [@b40]). Lantibiotics, including nisin, can have multiple mechanisms of action facilitated through the binding of lipid II and insertion into bacterial membranes ([@b3]; [@b2]; [@b18]). While Nisin A was first discovered in 1928 in fermenting milk cultures ([@b35]), five other naturally occurring variants of Nisin have been described. These are Nisin Z, F and Q, which like Nisin A are produced by *Lactococcus lactis*, and Nisin U and U2 which are produced by *Streptococcus* sp. There also exist a number of other more distantly related peptides within the Nisin subgroup of lantibiotics, such as subtilin ([@b20]), ericin A and ericin S ([@b39]; [@b32]), but which are not regarded as Nisin variants. Nisin Z, first isolated from *L. lactis* NIZO 22186 from a dairy product, differs from Nisin A by just one amino acid in the final active peptide, His27Asn ([@b31]) ([Fig. 1](#f1){ref-type="fig"}). Nisin F is produced by *L. lactis* F10 isolated from a freshwater catfish in South Africa, and it differs from Nisin A with respect to two amino acid residues, His27Asn (as in Nisin Z) and Ile30Val ([@b10]) ([Fig. 1](#f1){ref-type="fig"}). Nisin Q, produced by *L. lactis* strain 61‐14 isolated from a river in Japan, contains both of the substitutions observed in Nisin F as well as two additional variations, Ala15Val and Met21Leu ([@b15]) ([Fig. 1](#f1){ref-type="fig"}). Two more distantly related peptides, Nisin U and U2, are produced by *Streptococcus uberis* 42 (Nisin U) and *Streptococcus agalactiae* D536 (Nisin U2), and differ from Nisin A by 9 and 10 amino acids respectively ([@b41]) ([Fig. 1](#f1){ref-type="fig"}). These peptides are also three amino acid residues shorter than the other Nisin variants ([@b36]) ([Fig. 1](#f1){ref-type="fig"}). In addition to the genes which encode these structural peptides (and their accompanying leaders), Nisin production also requires the presence of genes required for transport (*nisT*; Nisin A designations are employed), leader cleavage (*nisP*), post‐translational modification (*nisB* and *nisC*), regulation (*nisRK*) and immunity (self‐protection; *nisI* and *nisEFG*) ([@b17]). While these genes are present in producers of all variants sequenced (the Nisin F and U2 gene clusters have not been sequenced), they can differ in gene order, as is the case with Nisin U ([@b41]) ([Fig. 2](#f2){ref-type="fig"}). The percentage similarity between the individual biosynthetic, regulatory and immunity proteins produced also varies ([Fig. 2](#f2){ref-type="fig"}), with the Nisin U genes being most distantly related to those associated with Nisin A. In recent years it has been shown that Nisin biosynthetic proteins can be harnessed, both *in vivo* and *in vitro*. This technology has facilitated the incorporation of lantibiotic‐associated post‐translational modifications into a range of unrelated peptides ([@b25]; [@b23]; [@b24]; [@b28]; for review see [@b29]). In addition to the long established use of Nisin as a food preservative, the high potency and multiple mechanisms of action have also been the focus of studies designed around using Nisin in clinical or veterinary applications against drug‐resistant pathogens. The efficacy of Nisin A, and to a much lesser extent Nisins Z and F, against methicillin‐resistant *Staphylococcus aureus* (MRSA), vancomycin‐resistant enterococci (VRE) and (heterogeneous) vancomycin intermediate *S. aureus*\[(h)VISA\] has been tested ([@b38]; [@b16]; [@b30]; [@b4]; [@b27]; [@b10]; [@b9]; [@b1002]). In this study, we use a bioengineering approach to convert a Nisin A‐producing strain into a producer of Nisins F, Q and Z. This bank of bioengineered strains provided us with the opportunity to directly compare the antimicrobial activity of these four natural Nisin variants.

![Comparison of natural Nisin variants.  A. Structure of Nisin A with modified residues indicated by grey circles/black text. Residues in Nisin F, Q, Z, U and U2 that differ from Nisin A are indicated by a white circle/grey text (Nisin F), dark grey circle/white text (Nisin Q), a dark grey circle/black text (Nisin Z) and black circles/white text (Nisin U/U2).  B. Alignment of unmodified Nisin variant and, for comparison purposes, subtilin propeptides. Residues that are conserved across all peptides are indicated by a black box and white text. Those conserved among the Nisin variants are indicated by a grey box and black text.](mbt0004-0375-f1){#f1}

![Nisin gene clusters. Analysis of the various Nisin loci illustrates that Nisin A, Z and Q all contain 11 open reading frames (ORFs) arranged in an identical manner on the chromosome, i.e. *nisA*(*Z*)(*Q*) *BTCIPRKFEG* ([@b13]; [@b19]; [@b42]). Nisin U also has 11 ORFs; however, they are arranged differently within the cluster ([@b41]). Homologous genes are represented by arrows of the same colour (the Nisin F and Nisin U2 gene cluster sequences are unavailable). Numbers underneath arrows show the % identity of the gene relative to its Nisin A‐associated counterpart \[pairwise alignment of protein sequences was carried out using Needleman--Wunsch global algorithms accessed via the European Bioinformatics (EBI) web server\].](mbt0004-0375-f2){#f2}

Results
=======

Bioengineering of *nisA*
------------------------

*Lactococcus lactis* NZ9800 is a non‐producing derivative of the Nisin A‐producing strain *L. lactis* NZ9700 ([@b26]) in which there is a deletion within the *nisA* structural gene. Production of Nisin A by NZ9800 can be restored through the introduction of *nisA in trans* on a vector such as pDF05, i.e. pCI372‐*nisA* ([@b14]). Here a number of new pCI372 derivatives were generated in the hope of providing a source of the peptides corresponding to the natural Nisin variants Nisin F, Q, Z, U and U2, while also determining if the Nisin A production machinery can, without manipulation, successfully be employed to produce these variants. As Nisin Z and Nisin F differ from Nisin A by one and two amino acids, respectively, a PCR‐based strategy was employed to alter the relevant codons in the pCI372‐*nisA*. However, as Nisin Q, U and U2 differ more dramatically from Nisin A, an alternative gene synthesis‐based strategy was employed to create the relevant genes. The synthesized genes were designed such that they deviated from the *nisA* sequence by as little as possible, including the retention of the NisA leader. In all instances, the newly generated pCI372 derivatives, i.e. pCI372*nisF*, pCI372*nisQ*, pCI372*nisZ*, pCI372*nisU* and pCI372*nisU2*, were sequenced to confirm the integrity of the newly created/introduced genes and each construct was introduced into *L. lactis* strain NZ9800.

Production of Nisin variants
----------------------------

Preliminary antimicrobial assays (deferred antagonism assays) were performed with *L*. *lactis* NZ9800 containing the various pCI372 constructs. NZ9800 containing pCI372*nisA* has previously been shown to produce active Nisin A ([@b14]), but we also observed that strains containing pCI372*nisF*, pCI372*nisQ* and pCI372*nisZ* all inhibited the *L. lactis* HP indicator strain ([Fig. 3](#f3){ref-type="fig"}). Thus deferred antagonism bioactivity assays against *L. lactis* HP established that these strains produced an active antimicrobial. However, strains containing pCI372*nisU* or pCI372*nisU2* did not inhibit this indicator, or any other of the indicator strains employed (data not shown) indicating that these strains did not produce a bacteriocin. Colony mass spectrometry detected the production of Nisins A, F, Q and Z from the relevant strains ([Fig. 3](#f3){ref-type="fig"}); no peaks were detected which would correspond to Nisin U and U2. Additional investigations were carried out to investigate the basis for the apparent non‐production of these peptides, which could be as a consequence of an inability to auto‐induce their own production ([@b12]; [@b5]) or the inability of the biosynthetic machinery to modify the bioengineered peptide or cleave the associated leader. These investigations employed mass spectrometric analysis of lysates of cells with and without induction with Nisin A‐containing supernatant. However, peptides of mass corresponding to those of U and U2 (modified, unmodified, with or without leader) were again not detected (data not shown). Thus the basis for the non‐production of these peptides is not apparent. We anticipate that the use of alternate expression systems, which differ more dramatically from that in a wild‐type cell (such as those used to introduce lanthionine residues into non‐nisin peptides ([@b34]; [@b25]; [@b33]; [@b23]; [@b24]; [@b28])), could be employed to generate Nisin U and U2. However, the inability of the Nisin A machinery in its natural form (i.e. not expressed from vectors) to generate Nisin U or Nisin U2 suggests that the classification of these peptides as true Nisin variants is debatable. It could be argued that these peptides, which unlike the other Nisin variants are not produced naturally by lactococci, should instead be regarded as members of the extended Nisin‐like peptide subgroup of lantibiotics ([@b7]; [@b32]), as is the case for subtilin (*Bacillus subtilis*) ([@b20]), ericin A/S (*B. subtilis*) ([@b39]), epidermin (*Staphylococcus epidermidis*) ([@b37]), pep 5 (*S. epidermidis*) ([@b21]) and gallidermin (*Staphylococcus gallinarum*) ([@b22]).

![The masses of Nisin A, F, Q and Z conform with those predicted previously i.e. 3353.53 Da ([@b43]) respectively. Bioactivity studies, in the form of deferred antagonism assays using 3 µl of spots of the respective overnight culture, were carried out with all four producers using *L. lactis* HP as an indicator.](mbt0004-0375-f3){#f3}

Comparison of the antimicrobial activity of Nisin A, F, Q and Z
---------------------------------------------------------------

The creation of strains of NZ9800 capable of producing Nisins A, F, Q and Z, provided us with an opportunity to compare the antimicrobial activity of equimolar concentrations of purified forms of these peptides in broth against a specific set of indicators. In addition to *L. lactis* HP, we chose *S. aureus* or *Enterococcus* sp. isolates, including many clinical isolates. These were ST 299 (MRSA), ST 525 (MRSA), EC 676 (VRE), EC 725 (VRE), VISA 22900, VISA 22781, hVISA 35197, hVISA 32683 and the laboratory strains *S. aureus* Newman and 8325‐4. It was apparent from these studies that the Nisin variants differ in their specific activities against selected targets ([Table 1](#t1){ref-type="table"}). Nisin F was most impressive, being the most active, or one of the most active, against the MRSA strain ST 525, EC 676, EC 725, VISA 22900, VISA 22781, hVISA 35197, *S. aureus* 8325‐4 and *L. lactis* HP. Nisin Z was most active against ST 299, hVISA 32683 and, together with Nisin F, HP but had contrastingly poor activity against ST 525, EC 676 and 8325‐4. Nisin F, Q and A exhibited similar potency against VISA 22900. This was the only target against which Nisin Q and Nisin A were among the most active variants.

###### 

MIC values of Nisin A, F, Q and Z against representative targets.

                                   Nisin A  (mg l^−1^)   Nisin F  (mg l^−1^)   Nisin Q  (mg l^−1^)   Nisin Z  (mg l^−1^)
  -------------------------------- --------------------- --------------------- --------------------- ---------------------
  ST 299 (MRSA)                    5.2                   5.1                   10.3                  2.6
  ST 525 (MRSA)                    10.4                  1.2                   2.5                   20.8
  EC 676 (VRE)                     20.9                  5.1                   10.3                  \> 83.2
  EC 725 (VRE)                     10.4                  2.5                   10.3                  5.2
  VISA 22900                       41.9                  41.4                  41.5                  \> 83.2
  VISA 22781                       \> 83.8               82.8                  \> 83.1               \> 83.2
  hVISA 35197                      10.4                  2.5                   5.1                   5.2
  hVISA 32683                      2.6                   2.5                   5.1                   1.3
  *Staphylococcus aureus* Newman   10.4                  5.1                   5.1                   20.8
  *Staphylococcus aureus* 8325‐4   20.9                  5.1                   10.3                  41.6
  *Lactococcus lactis* HP          0.13                  0.064                 5.1                   0.066

The standard deviation in all cases is 0 reflecting identical triplicate results.

Discussion
==========

In this study we take advantage of a peptide bioengineering strategy, which we have employed previously to generate completely novel Nisin A derivatives ([@b14]), to facilitate the creation and subsequent first direct comparison of what could be argued to be the four 'true' Nisin variants. The description of Nisins F, Q and Z as 'true' variants of Nisin A stems from our observation that Nisins U and U2 cannot be produced by a system which most closely resembles that present in natural Nisin A‐producing strains. This is despite the fact that the *nisU* and *nisU2* genes were synthesized to incorporate the Nisin A leader and were designed to employ *L. lactis* codon utilization preferences and Nisin A was added exogenously to ensure that induction of the P*nis* promoter was not an issue. Unfortunately, our inability to detect peptides corresponding to any form of the Nisin U and U2 peptides means that the basis for this non‐production is not known. It is not anticipated that a lack of cross‐immunity \[which, in the case of lantibiotics, involves an ABC transporter (LanEFG) and/or immunity protein (LanI)\] is responsible as it has previously been established that Nisin U‐, Nisin Z‐ and Nisin A‐producing strains are all resistant to both Nisin A and Nisin U ([@b41]). Thus presumably the non‐production of Nisin U and U2 stems from an impact on the transcription of the structural peptide‐encoding genes or a failure of one or more of the biosynthetic (NisBC), leader removal (NisP) or export (NisT) proteins to recognize the Nisin U/U2‐encoding peptides. The former possibility would most likely result due to an inability of the NisRK system to recognize and auto‐induce production to detectable levels, yet the addition of exogenous Nisin A did not rectify the problem. Were the latter alternative to be true, one might expect that unmodified or partially modified peptides would be detected. However, the expression system employed may have limited our ability to detect such peptides.

There have been only a few studies which have assessed the specific activity of more than one Nisin variant against the same indicator. Although a comparison of the minimum inhibitory concentrations (MICs) of Nisin A and Z revealed that both were equally active against *Micrococcus flavus DSM* 1719, *Streptococccus thermophilus* Rs, *Clostridium tyrobutyricum* BZ15, *L. lactis* ssp. *cremoris* BA3, *Bacillus cereus* P7 and C5 and *Listeria monocytogenes* 13 and 669 ([@b11]), a more recent comparison of the activities of Nisin A, Q and Z against a range of strains showed that relative potencies did vary. Although all three were equally active against *Bacillus coagulans* JCM 2257, *B. subtilis* JCM 1465 and *Micrococcus luteus* IFO 12708, Nisin A and Z were the most active against *Bacillus circulans* JCM 2504, *L. lactis* ATCC 19435 and *Lactobacillus sakei* JCM 1157. Nisin A was the most active against *Pediococcus pentosaceus* JCM 5885 and *Leuconostoc mesenteroides* JCM 6124, Nisin A and Q were the most potent against *Enterococcus faecalis* JCM 5803. Nisin Q was the most active against *Lactobacillus plantarum* ATCC 14917 while Nisin Q and Nisin Z were more active than Nisin A against *Listeria innocua* ATCC 33090 ([@b42]). Here, in addition to focusing to a greater extent on clinical pathogens, Nisin F was also available for direct comparison. The inclusion of Nisin F proved to be particularly important as it proved to be the most active peptide against many of the targets utilized. Our initial deferred antagonism bioactivity assays against *L. lactis* HP ([Fig. 3](#f3){ref-type="fig"}) established that the Nisin F producer generated the largest zone, followed by Nisin Z, Nisin Q and lastly, Nisin A. However, it was expected that these results would not provide an accurate representation of relative specific activity given the superior diffusion properties of Nisin Z in agar ([@b11]) and potential auto‐induction related issues connected with Nisin Q production in a derivative of a producer of another Nisin variant ([@b42]). For this reason we focused on MIC assays with equimolar concentrations of purified peptide. Nisin F proved to be most impressive when assayed in this way, consistently being the most, or second most, active peptide. While the activity of Nisin F was, like the other variants, greatly reduced against the VISA isolates, its activity against other clinical *S. aureus* (i.e. hVISA and MRSA) was impressive. Previous Nisin F studies established its *in vitro* efficacy against two clinical sinusitis‐associated *S. aureus* strains ([@b10]) and *in vivo* activity against an MRSA strain using a Wistar rat pneumonia model ([@b9]). However, here, as a consequence of the direct comparison of the activities of Nisin A, F, Q and Z against a range of *S. aureus* targets, it is apparent that, of these four peptides, Nisin F is most deserving of further investigation as an anti‐*S. aureus* chemotherapeutic option.

Experimental procedures
=======================

Bacterial strains and culture conditions
----------------------------------------

Two MRSA strains, ST 299 and ST 525, and two VRE strains, EC 676 and EC 725, were obtained from the Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency (HPA), Colindale, UK. Two VISA strains, VISA 22781 and VISA 22900, and two hVISA strains, hVISA 35197 and hVISA 32683, were obtained from the Bristol Centre of Antimicrobial Research and Evaluation (BCARE), UK. Two methicillin‐sensitive *S. aureus* (MSSA) strains were also assayed; i.e. *S. aureus* NCTC 8325‐4 and *S. aureus* Newman. *Staphylococcus aureus* strains were cultured in Mueller Hinton broth at 37°C with aeration. VRE strains were cultured in cation‐adjusted Mueller Hinton broth in accordance with NCCLS microbroth dilution guidelines ([@b1]) at 37°C without aeration. *Lactococcus lactis* HP and NZ9800 were grown at 30°C in M17 broth (Oxoid) supplemented with 0.5% glucose (GM17) without aeration.

Molecular biology techniques
----------------------------

pDF05 (pCI372‐*nisA*) ([@b14]) was used as a template for PCR‐based bioengineering of *nisA*. Oligonucleotides (primers listed in [Table 2](#t2){ref-type="table"}) were designed to introduce the individual amino acid changes to generate Nisin F‐ and Nisin Z‐encoding genes (MWG Biotech, Germany) and PCR amplification using the high‐fidelity KOD polymerase (Novagen). Amplified products were treated with DpnI (Stratagene) at 37°C for 60 min in order to digest the template DNA and then purified using QIAquick PCR purification kit (Qiagen). Following transformation into *Escherichia coli* Top 10 cells, plasmid DNA from candidates was isolated and successful alterations were detected using a 'check' oligonucleotide (i.e. an oligonucleotide containing a 3′ sequence designed to amplify the bioengineered gene only) together with the 5′ Nisin A to Z for primer in the case of Nisin Z and the 5′ Nisin A to F for primer in the case of Nisin F. The integrity of the bioengineered genes was confirmed by DNA sequencing (MWG Biotech, Germany). Nisin Q‐, Nisin U‐ and Nisin U2‐encoding genes (GenBank Accession Nos GU384319, GU384320 and GU384321 respectively) were generated by gene synthesis (GENEART, Regensburg, Germany) and were cloned into pCI372 to generate pCI372*nisQ*, pCI372*nisU* and pCI372*nisU2*. The various pCI372 constructs were then introduced into *L. lactis* strain NZ9800 as described previously ([@b14]) and the purification of each of the individual variants was carried out as described ([@b1001]).

###### 

PCR primers used in this study.

  Primer name            Primer sequence
  ---------------------- ------------------------------------------------------------
  Nis A to Z for         5′‐P‐CAGCAACTTGTAACTGTAGTATTCACGTAAGCAAATAACCA‐3′
  Nis A to Z rev         5′‐TGAATACTACAGTTACAAGTTGCTGTTTTCATGTTACAACC‐3′
  Nis A to Z check       5′‐GAAAACAGCAACTTGTAAC‐3′
  Nis A to F for         5′‐P‐CAG CAA CTT GTA ACT GTA GTG TTC ACG TAA GCA AAT AA‐3′
  Nis A to F rev         5′‐GCT TAC GTG AAC ACT ACA GTT ACA AGT TGC TGT TTT CAT‐3′
  Nis A to F check       5′‐AAC TTG TAA CTG TAG TGT T‐3′
  pCI372for              5′‐ACCTCTCGGTTATGAGTTAG‐3′
  pCI372rev              5′‐CGGGAAGCTAGAGTAAGTAG‐3′
  Nisin_for (EcoRI)      5′‐AGGAATTCTAGTCTTATAAC‐3′
  NisinQ_rev (XbaI)      5′‐GCTCTAGATTATTTGCTTAC‐3′
  NisinU/U2_rev (XbaI)   5′‐GATCTAGATTATCCAAAATG‐3′

Antimicrobial activity assays
-----------------------------

Deferred antagonism assays were performed by spotting 3 µl from an overnight culture of each variant‐producing *L. lactis* onto the surface of GM17 agar and growing overnight at 30°C. The resultant spots were subsequently overlaid with GM17 agar (0.75% w/v agar) seeded with the indicator strain *L. lactis* HP. Plates were then incubated at 30°C overnight after which time zones of clearing were measured and compared. Minimum inhibitory concentration studies were carried out in triplicate in 96‐well microtitre plates (Sarstedt) as described previously ([@b1002]). In brief, a 10 ml overnight culture of the producer strain in question was subcultured into fresh media, 10 ml of GM17 broth, and allowed to grow to log phase, i.e. OD~600~ 0.5. A Nisin stock solution of 2.5 µM (or 10 µM in the case of more resistant strains) was prepared by weighing pure lyophilized powder and suspending in the correct volume of GM17 broth to obtain the desired concentration. Twofold serial dilutions of the peptide were added to the target strain in the microtitre plate. Assays were carried out in triplicate and biological replicates were also employed. The MIC concentration was the lowest concentration which prevented growth of the target after 16 h incubation at 37°C.

Investigations to detect the presence of peptides which are unmodified and/or uncleaved
---------------------------------------------------------------------------------------

Overnight cultures of the bioengineered strains were subject to mass spectrometric analysis following centrifugation of 1 ml volumes of the culture and lysis of the resulting pellet with glass beads and vigorous vortexing. Dilutions were made prior to mass spectrometric analysis.

To address the possibility that induction by Nisin A may be required, further investigations were carried out. Overnight cultures of the relevant strains were re‐inoculated into fresh media and allowed to reach log phase (OD~600~ 0.5), at which point varying levels of exogenous Nisin A (supernatant obtained from an overnight of Nisin A) were added to these log‐phase cultures. After incubation for a further hour at 30°C, cell lysis was again carried out as described above before proceeding for mass spectrometric analysis. Yet again however, no peptides of relevant mass were detected.
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